🟢 96/100

This product looks safe

  • Manganese: 12mg is 1.1× the Tolerable Upper Intake Level (11mg)
  • 60% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Manganese: 12mg is 1.1× the Tolerable Upper Intake Level (11mg)

Label Data

4 Capsule(s) Serving Size
22.5 Servings
Other Combinations Product Type
60% Evidence Coverage

Supplement Facts — Evidence Check

500 mcg (600% DV)
📊 4.2× RDA — above typical dose 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.5mg
1000 IU (250% DV)
✅ 1.7× RDA — within safe limits 📚 604 studies (Tier A: 16, B: 251)
RDA 0.015mg This product: 0.025mg UL 0.1mg
5 mg (30% DV)
✅ Within RDA (0.5× RDA of 11 mg) 📚 258 studies (Tier A: 6, B: 134)
RDA 11mg This product: 5mg UL 40mg
1 mg (50% DV)
✅ 1.1× RDA — within safe limits 📚 36 studies (Tier A: 0, B: 11)
RDA 0.9mg This product: 1mg UL 10mg
12 mg (600% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.1× (UL: 11 mg) 📚 8 studies — no high-quality reviews
RDA 2.3mg This product: 12mg UL 11mg
📊 Market median: 600.0mg (79 products) 📚 24 studies (Tier A: 0, B: 6)
This product: 1350mg
organic Rosehips powder
500 mg
📊 Market median: 108.0mg (8 products) 📚 9 studies (Tier A: 0, B: 4)
This product: 250mg
150 mg
📊 Market median: 200.0mg (136 products) 📚 3 studies — no high-quality reviews
This product: 150mg
1 mg
📊 Market median: 3.0mg (58 products) 📚 2 studies — no high-quality reviews
This product: 1mg UL 20mg

Other Ingredients

Vegetarian Capsule

Label Claims — Verification

All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions (Adults): Take four (4) capsules twice per day or directed by your doctor.

⚠️ Warnings & Precautions

Caution: Keep out of reach of children.

If you are pregnant, lactating, taking any medications, or have a medical condition, consult your doctor.

Discontinue use if adverse reaction occurs. Do not use if seal is damaged or missing.

Adverse events may be reported above.

🧪 Formulation Notes

Every day, your joints undergo normal wear and tear from daily activities or the stress caused by exercise. These daily activities can lead to joints, ligaments, or tendons that are stiff and sore. Lidtke designed ArthroCare to: Promote flexibility and movement Maintain healthy joints free of minor pain Support joint and cartilage health

ArthroCare is free of glucosamine or other simple sugars that may aggravate glucose intolerance or yeast conditions.

Superb quality since 1994 Advanced extra strength formula For healthy joints Strong ligaments & Tendons Purest on the planet

Additional Information

Thank you for choosing ArthroCare by Lidtke. We sincerely wish the best of health for you and your family.

Lidtke stands behind each product and guarantees customer satisfaction for 365 days from the date of purchase.

Keep lid tightly closed. Keep in a cool, dry place.

Product Details

UPC / SKU 6 30610 00368 1
DSLD Entry Date 2021-11-19
Product Type Other Combinations
Form Capsule
Brand Lidtke
DSLD ID 257176
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →